Andre Kalil, MD MPH

@drandrekalil.bsky.social

Practicing Doc, Transplant ID Director, ID/Critical Care, Clinical Researcher & Trialist. Professor, University of Nebraska Medical Center, Omaha.

Considering where to publish your next study? JAMA Network Open offers rapid online publication, broad dissemination, extensive media attention, and an Impact Factor of 11.7—all designed to maximize the visibility and impact of your research. Learn more: ja.ma/4ftmoOf

Why Publish in JAMA Network Open? Highlights speed (2 days decision without review, 46 with review), extensive reach (+30,600 media mentions in 2025, broad multimedia coverage), & impact (11.7 Journal Impact Factor, +41M annual views/downloads). JAMA Network Open. logo shown.

Excited to share our latest publication in AIDS! We performed one of the largest multi-ancestry genome-wide association studies of cardiovascular disease in people living with HIV using the Million Veteran Program. We identified a novel genetic locus near NAT8 associated with CVD risk.

BildBild

Great to see our new paper out in Nature Communications. In it we describe three novel phenotypes in lungs of patients with pneumonia. Pn1 -a non-neutrophil driven lung injury phenotype, Pn2-a balanced immune response with best recovery and Pn3-persistent inflammation driven by immature neutrophils

Pulmonary inflammation in severe pneumonia is characterised by compartmentalised and mechanistically distinct sub-phenotypes

Nature Communications - Analysis of cell samples from pneumonia patients may indicate specific phenotypes associated with disease. Here the authors use a multi-omics approach to analyse...

rdcu.be

Congrats to my colleagues for this interesting analysis. Looking at patients who met DOTS criteria and receive dalbavancin in our hospital, they differ from the DOTS trial Younger, more IDU, more R-sided IE (less SSTI), and more persistent bacteremia. Yet, outcomes similar #IDSky

JAMA Network Open@jamanetworkopen.com · 2mo ago

In clinical practice, patients with #Bacteremia receiving dalbavancin were younger and more likely to have substance use or housing instability than those in the DOTS trial, but completed therapy with similar low failure rates. ja.ma/4odctAk

Table 2. Cohort Outcomes Comparisons. DOTS trial (n=100) shows 80% overall clinical success at day 70 & 73% composite efficacy, vs. clinical dalbavancin recipients (n=31) with 65% and 61% respectively.